Short answer
Inmune Bio, Inc. (INMB) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$5M
- +44.5% YoY
- EPS (diluted)
- −$0.20
- +53.5% YoY
Source: XBRL data from the Inmune Bio, Inc. (INMB) Q1 2026 10-Q on SEC EDGAR. USD.
Inmune Bio, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0 vs $50,000 YoY, reflecting no license-agreement revenue
- Operating margin -100.0% vs -19,810.0% YoY
- R&D expense $3.6M vs $7.6M; CORDStrom/INKmune costs rose $1.0M
- Cash $21.4M vs $24.8M at December 31, 2025; operating cash use $3.4M vs $6.8M
- CORDStrom MAA and BLA filings targeted for 2026; losses and cash use expected to increase
Risk Factors
- No risk-factors section provided in the submitted text
- No newly added, updated, regulatory, operational, competitive, market, or financial risks identifiable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inmune Bio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.